Patrick Mahieux – General Manager, ABL Europe
Patrick Mahieux, general manager of ABL Europe, a CDMO specialized in the provision of viral vectors, discusses the company’s history within the Institut Mérieux and, the unique and flexible strategy…
The Swiss company SIGVARIS, 100% family-owned since it was founded, is the global market leader in the manufacture of medical compression garments and celebrated its 150th anniversary in 2014. The company was established in 1864 in Winterthur. For about 100 years, SIGVARIS produced “rubber-elastic textiles”, which it sold both in Switzerland and abroad.
From 1958 to 1960, the company collaborated with Dr. Karl Sigg and developed a medical compression stocking to improve venous function and relieve venous-related conditions. The product portfolio was expanded in 2009 when the WELL BEING and SPORTS lines were added to the main MEDICAL line. WELL BEING stockings have a preventive function and relieve the early symptoms of leg conditions. SPORTS products improve athlete performance and recovery time.
The company can look back at a successful track record as it moves continuously towards the future, in keeping with its motto “Every day a step further”. Customers around the world include pharmacies, chemists, orthopaedic and medical specialist stores as well as doctors and hospitals. The Group produced about 8 million pairs of stockings in 2014 and generated revenue of around CHF 250 million.
SIGVARIS Group
The Swiss Group SIGVARIS has its headquarters in Switzerland and is the global market leader in the manufacture of medical compression garments. It employs about 1,400 people and has its own production plants in Switzerland, France, the US and Brazil. SIGVARIS is close to its customers, having subsidiaries in Germany, Austria, England, Italy, Canada, China, Australia and the United Arab Emirates as well as distributors in more than 70 countries on all continents. The Group pursues an international growth strategy on the solid foundation of 150 years of success.
Contact
Rue Barthélémy Thimonnier, 42170 Saint-Just-Saint-Rambert, France
+33 4 77 36 08 90
Patrick Mahieux, general manager of ABL Europe, a CDMO specialized in the provision of viral vectors, discusses the company’s history within the Institut Mérieux and, the unique and flexible strategy…
Jaques Chevallet, CEO of Arkopharma, a European leader in herbal medicines and dietary supplements, discusses the company’s development over recent years while sharing his assessment on the current condition of…
Elizabeth Ducottet, the 5th generation CEO of French family company Thuasne, shares the group’s history and goes on to explain how it has evolved into a professionally and innovatively driven…
Marc Oczachowski, CEO of EDAP TMS, a French medtech and global leader in therapeutic ultrasound, elaborates on the history of the company while discussing their newest innovation for the noninvasive…
In an exclusive interview, Dominique Le Guludec, president of the French National Authority for Health (Haute Autorité de Santé (HAS)), offers her insider comments on the changes in French healthcare…
David Lescuyer, managing director of Skyepharma, a specialized CDMO, reflects on the past three years of the company as it transitioned from a drug delivery platform to a fully-fledged service…
Dr Marc-Alexander Burmeister, president of B. Braun in France, shares the exciting changes to come for B. Braun globally and in France, and discusses the shifting environment of healthcare in…
Françoise Alliot-Launois, VP of the French League Against Rheumatism (AFLAR), discusses the issues around bone and joint infections in France, AFLAR’s work to help patients suffering from these diseases, and…
Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service…
Abbvie France’s Pierre-Claude Fumoleau outlines his strategic priorities for the affiliate, AbbVie’s unique corporate culture and ethos, and how he envisions upcoming regulatory reforms playing out in France. We…
Denis Delval, CEO of iconic French pharma firm LFB since December 2017, discusses his key priorities to build the new LFB. My vision is that we should be strong…
Biotest’s Olivier Samama outlines the changes that the takeover of the company has had on the French affiliate, the country’s plasma market and pricing policy. The product offering remains…
See our Cookie Privacy Policy Here
